Clinical Trial Update: An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits [Phase 4]

View source ↗

Summary

This document reports the completion of a Phase 4 extension study evaluating the efficacy and safety of rivastigmine in patients with traumatic brain injury who…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: Novartis | Conditions: Traumatic Brain Injury With Persistent Cognitive Deficits | Phase 4 | Status: COMPLETED